643 results about "Oral medication" patented technology

The application belongs to the technical field of animal models for basic scientific research, and particularly relates to a method for establishing an acute lung injury animal model, which comprises the following steps: sending a podophyllotoxin or a podophyllotoxin reagent into a rat body through oral administration or intragastric perfusion to obtain the acute lung injury animal model. The method for establishing the acute lung injury animal model provided by the application uses the podophyllotoxin as an inducer for establishing a mouse acute lung injury model, and the mouse can orally take or intragastrically perfuse the podophyllotoxin to achieve the method, without needing a special medicine injection device, so that the method is simple in medicine taking, few in experimental steps, and does not need complex surgical operations.

Provided herein are formulations for oral delivery or administration of therapeutic nucleic acids. An oral formulation can include: a nucleic acid; at least one casein protein; and a chitosan. In some embodiments, the formulations are liposome-free formulations having no cationic lipids typically used as transfection reagents in conventional nucleic acid formulations for oral delivery. The formulations provided herein find use in treating a condition associated with inflammation and / or fibrosis, or a cardiometabolic disorder by oral administration.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

This invention belongs to the field of pharmaceutical formulation technology and provides a vinpocetine suspension and its preparation method. The vinpocetine suspension of this invention comprises the following raw materials in specific mass parts: vinpocetine, a suspending agent, a solubilizer, a stabilizer, and water. The vinpocetine suspension of this invention is suitable for oral administration. The excipients in the suspension include a suspending agent, a solubilizer, and a stabilizer. The solubilizer inhibits the aggregation of vinpocetine nanoparticles and improves the solubility and dispersion uniformity of vinpocetine nanoparticles in water. The suspending agent and stabilizer together construct a spatially stable structure, ensuring the suspension and dispersion of vinpocetine nanoparticles and resisting sedimentation. The suspending agent, solubilizer, and stabilizer work synergistically to achieve nanoscale distribution and uniform dispersion and suspension of vinpocetine, significantly improving the bioavailability of vinpocetine. High-pressure homogenization achieves nanoscale distribution of vinpocetine, with a particle size of 200-300 nm.

The present invention relates to compounds comprising a GLP-1 receptor agonist and an amylin receptor agonist. The invention also relates to pharmaceutical formulations suitable for, but not limited to, oral administration, comprising such compounds. The compounds and pharmaceutical formulations comprising the same are useful in the medical treatment of subjects suffering from overweight, obesity and associated co-diseases.

The present disclosure provides methods of treating cerebral cavernous malformations and Devic's disease with ROCK2 inhibitors. The present disclosure also provides pharmaceutical formulations for oral administration of ROCK2 inhibitors for the treatment of cerebral cavernous malformations and Devic's disease.

A composition contains a BCS Class II or IV drug that is acid-base solubilized with a pharmaceutically acceptable acid, and which is complexed with β-cyclodextrin. The β-cyclodextrin complexed drug exhibits enhanced bioavailability. The drug may be formulated for oral administration and / or to exhibit rapid release when administered. Preferable compositions may contain no crosslinked or polymerized non-active components.

The application belongs to the field of neuropharmacology and medicine, and particularly relates to application of taurine cholic acid in preparation of a drug for preventing or treating Alzheimer's disease. Through animal model experiment verification, the A beta lateral ventricle injection is used to prepare an AD mouse model, and after oral administration of TCA for 2 weeks, cognitive behavior and pathological indexes are significantly improved.

The application discloses a kind of oral administration device, it is related to medical instrument technical field, including injection administration component, the injection administration component includes administration needle tube, the injection administration component is connected with the mouth support plate by sliding connection component, the side of the mouth support plate is provided with the mouth support device for adjusting the opening angle thereof.The injection administration component is connected with the mouth support plate by sliding connection component in the application, the side of the mouth support plate is provided with the mouth support device that can adjust the opening angle, the mouth opening and injection administration function integration are integrated, effectively solve the difficulty of long time maintaining oral cavity opening state when oral patient is treated, the mouth support device needs to be operated by doctor with single hand, single hand administration leads to low operating efficiency, and the problem that conventional mouth support device cannot realize opening angle accurate regulation and stable clamping, angle rebound and oral cavity closure are prone to occur, and then affect the smooth operation of administration.

The invention discloses a pharmaceutical composition and application thereof in preparation of a medicine for treating sudden deafness, pharmacodynamic data shows that all components of the composition have a synergistic effect, the solubility and bioavailability of the composition in water can be remarkably improved, and the pharmaceutical composition can be used for treating sudden deafness. Through an oral administration mode, the hearing threshold of cochlear ischemia reperfusion model animals can be remarkably reduced, release of inflammatory factors such as serum IL-1beta and TNF-alpha is inhibited, oxidative stress is relieved (the malondialdehyde level is reduced), so that multi-target synergistic treatment of sudden deafness is realized, the effect is remarkable, the defects that an existing drug is single in target and inconvenient to administrate are overcome, and the application prospect is wide. The important clinical application value is realized.

The invention belongs to the technical field of oral medicine preparations, and particularly relates to a microcrystal suspension multi-ball soft capsule and a preparation method and application thereof.The microcrystal suspension multi-ball soft capsule is of a three-level structure formed by a shell, temperature-sensitive hydrogel and medicine-carrying microcrystal balls, and the medicine-carrying microcrystal balls are in a three-level structure under the spatial constraint effect of the temperature-sensitive hydrogel. The medicine-carrying microcrystalline balls are prevented from settling or freely moving; after the medicine is orally taken and enters a body, the shell is rapidly disintegrated, the temperature-sensitive hydrogel is slowly corroded, the medicine-carrying microcrystalline balls are released accordingly, and it is ensured that the medicine nanocrystals are stably dissolved out. Besides, in the preparation process, only conventional equipment, such as a high-pressure homogenizer and a soft capsule pressing machine, is needed, and a special nano synthesis or crosslinking process is not needed; the preparation process is easy to control and meets the large-scale production requirement.

The invention discloses pediococcus acidilactici and application thereof in preparation of a medicine for preventing or treating diarrhea of yak calves, and belongs to the technical field of microorganisms. The pediococcus acidilactici is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: M20252012, and the preservation date is September 12, 2025. The strain has remarkable bacteriostatic activity on yak-derived multi-drug-resistant escherichia coli (the accession number of NCBI is PP859186). After the probiotic preparation is orally taken, the yak calf diarrhea induced by escherichia coli can be effectively relieved, the diarrhea rate and the inflammatory factor level are remarkably reduced, the oxidation resistance is improved, the flora structures of intestinal bacteria and fungi are adjusted, and the micro-ecological balance is restored. The invention provides a safe, green and efficient alternative antibody product which is suitable for the plateau yak breeding industry.

The present invention relates to immunoglobulin single variable domains (ISVDs) for the treatment of diseases by the enteral, e.g. oral, delivery. In particular, the present invention provides ISVDs comprising sequences with a high percentage of sequence identity to SEQ ID NO: 1 for such enteral administration. Such sequences were identified as extraordinarily stable in the gastrointestinal tract, which prevents their degradation and thereby allows them to exert a strong therapeutic effect.

The application relates to the medical technical field, in particular to application of neoline in treatment of Parkinson's disease. 19 The C 19 The type-II diterpene alkaloid neoline can significantly improve movement disorder in a MPTP-induced Parkinson's disease model mouse, the drug efficacy is equivalent to that of the positive drug madopar, the effective dose is much lower than that of the positive drug, the administration mode is oral administration, drug compliance and use convenience are good, and the neoline can be used for development of anti-Parkinson's disease drugs.

This invention provides a method for treating a pulmonary arterial hypertension with reduced incident of side effect using a controlled release pharmaceutical composition of selexipag or its active metabolite, wherein the controlled release pharmaceutical composition of selexipag or its active metabolite following oral administration with an alcoholic beverage reduces incidence of at least one side effect associated with the selexipag or its active metabolite compared to the immediate-release dosage form comprising the same amount of the selexipag or active metabolite thereof.

The invention discloses application of eupatolide in preparation of a medicine for preventing and treating inflammatory bowel disease, application of eupatolide in preparation of a medicine for preventing and treating inflammatory bowel disease and application of a medicine preparation containing eupatolide in preparation of a medicine for preventing and treating inflammatory bowel disease, and researches that eupatolide (EPT) can be used for preparing the medicine for preventing and treating inflammatory bowel disease through targeting pyruvate kinase isoenzyme 2 (PKM2, Gene ID: 5135). The inflammatory response, glycolysis metabolism and mitochondrial homeostasis are synergistically regulated and controlled, so that the inhibition effect on the inflammatory bowel disease is exerted. Meanwhile, EPT has the advantages of being low in dosage, feasible in oral administration, free of obvious toxic and side effects and the like, and a solid experimental basis is provided for further developing EPT into candidate drugs for preventing and treating inflammatory bowel diseases.

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

Disclosed are 1,2,4,5-tetraoxane compounds and derivatives thereof having anticancer properties. Disclosed are pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for delivering the compounds to a subject in need thereof. In addition to the compounds, the pharmaceutical compositions or formulations can include one or more active agents, such as one or more additional anticancer agents. Also disclosed are methods of treating, mitigating, or treating or ameliorating one or more symptoms associated with cancer in a subject. The methods include (i) administering to a subject in need thereof an effective amount of a compound. The compound can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. The compound can selectively kill cancer cells and / or cancer stem cells, but not non-cancer cells, by inducing ferroptosis in the cancer cells and / or cancer stem cells.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

To address the issues of the insolubility of As2O3 and the lack of bioavailability and provide a lyophilized composition comprising arsenic that makes it bioavailable, and further to provide methods for production thereof, and methods for treating malignancies such as tumor or cancer by orally administering the lyophilized composition comprising arsenic.SOLUTION: A method for preparing a lyophilized composition comprising arsenic (LCCA) comprises the steps for: (A) solubilizing As2O3 powder in an aqueous medium to form an As2O3 solution; and (B) lyophilizing the As2O3 solution.SELECTED DRAWING: None

The invention belongs to the technical field of medicines, and particularly relates to a triptolide nano-skeleton and a preparation method and application thereof, and the triptolide nano-skeleton comprises the following components by mass: 11%-20% of triptolide, 20%-60% of polyacrylic resin, and 20%-60% of mesoporous silica. The triptolide nano-skeleton provided by the invention is mainly composed of a drug triptolide, a high-molecular polymer material polyacrylic resin and a carrier material mesoporous silica, and a mixture formed by triptolide and polyacrylic resin is uniformly loaded on the mesoporous silica to form a solid preparation suitable for oral administration. The dissolution rate and oral absorption of the triptolide are remarkably increased, the treatment safety is ensured, meanwhile, the curative effect of the triptolide on rheumatoid arthritis is effectively enhanced, and the triptolide tablet has a good application prospect.

The present disclosure provides peptides for reducing weight and / or preventing weight gain comprising a GLP-1R agonist. As described herein, the GLP-1R agonist can be administered orally to a subject.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, sublingual administration, topical administration, transdermal administration, or combinations thereof and uses thereof.

A pharmaceutical liquid dosage form of Trientine and / or pharmaceutically acceptable salts thereof is provided, which are suitable for oral administration. A process of preparing the liquid dosage form and use for treatment of Wilson's disease and related diseases are also provided.

Orally administrable nanoparticle complexes of biological molecules and biopolymers are described herein, and include formulations for the oral administration of peptides, proteins, nucleic acids, and antibodies.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The invention relates to the non-therapeutic nutricosmetic use of a composition in a form suitable for oral administration comprising a wheat extract in a physiologically acceptable medium. The invention is characterized in that the wheat extract contains 35-40% of triglycerides and diglycerides, 20-30% of glycolipids, 7-10% of phospholipids and 2-4% of ceramides and glycosylceramides, by weight relative to the total weight of the extract, and is used to reduce excessive sebum secretion in the skin of the face.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The present invention relates to a pharmaceutical composition for oral administration, the pharmaceutical composition comprising: a) immediate-release granules comprising i. an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and ii. a filler; and b) sustained-release pellets comprising: i. a pellet core comprising (1) an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and (2) a filler; and ii. on the pellet core iii. A sustained-release pellet comprising a subcoat provided on the subcoat, the content of which is 10 to 20% by weight based on the weight of the pellet core and contains a film-forming agent, and iii. a sustained-release coating provided on the subcoat, the content of which is 25 to 100% by weight based on the weight of the pellet core coated with the subcoat and contains a film-forming agent, wherein the amount of active ingredient in the immediate-release granules accounts for 70 to 80% by weight of the total weight of active ingredients in the pharmaceutical composition, and the amount of active ingredient in the sustained-release pellets accounts for 20 to 30% by weight of the total weight of active ingredients in the pharmaceutical composition. In yet another aspect, the present invention relates to a method for producing a pharmaceutical composition and a pharmaceutical composition for use in a method of pretreatment of cancer.